Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Earns Outperform Rating from Analysts at Wedbush

Wedbush assumed coverage on shares of Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) in a research report released on Thursday morning, MarketBeat reports. The firm issued an outperform rating and a $22.00 price target on the stock.

Separately, William Blair reiterated an “outperform” rating on shares of Telix Pharmaceuticals Limited American Depositary Shares in a research report on Wednesday, March 12th.

Telix Pharmaceuticals Limited American Depositary Shares Trading Down 3.4%

Shares of TLX stock opened at $16.77 on Thursday. The stock has a 50 day moving average of $16.76 and a two-hundred day moving average of $16.85. Telix Pharmaceuticals Limited American Depositary Shares has a 12 month low of $13.61 and a 12 month high of $30.36.

Hedge Funds Weigh In On Telix Pharmaceuticals Limited American Depositary Shares

An institutional investor recently bought a new position in Telix Pharmaceuticals Limited American Depositary Shares stock. ABC Arbitrage SA bought a new position in Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 26,939 shares of the company’s stock, valued at approximately $451,000.

Telix Pharmaceuticals Limited American Depositary Shares Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.